ALSUntangled 53: Carnitine supplements

References

• Carnitine Fact Sheet for Health Professionals. NIH Office of Dietary Supplements website. Available at: https://ods.od.nih.gov/factsheets/Carnitine-HealthProfessional/ Updated October 10, 2017. Accessed January 1, 2020.
   Google Scholar
• El-Gharbawy A, Vockley J. Inborn Errors of metabolism with myopathy: defects of fatty acid oxidation and the Carnitine Shuttle System. Pediatr Clin N Am. 2018;65:317–35.
   PubMed Web of Science ®Google Scholar
• Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V. Carnitine and hemodialysis. Am J Kidney Dis. 2003;41:S116–S122.
   PubMed Web of Science ®Google Scholar
• Sanjak M, Paulson D, Sufit R, Reddan W, Beaulieu D, Erickson L, et al. Physiologic and metabolic response to progressive and prolonged exercise in amyotrophic lateral sclerosis. Neurology. 1987;37:1217–20.
   PubMed Web of Science ®Google Scholar
• Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler and Frontotemporal Degen. 2014;15:362–70.
   PubMed Web of Science ®Google Scholar
• Tsitkanou S, Gatta PD, Foletta V, Russell A. The role of exercise as a non-pharmacological therapeutic approach for amyotrophic lateral sclerosis: beneficial or detrimental? Front Neurol. 2019;10:783.
   PubMed Web of Science ®Google Scholar
• Fielding R, Riede L, Lugo J, Bellamine A. L-carnitine supplementation in recovery after exercise. Nutrients. 2018;10:349.
   PubMed Web of Science ®Google Scholar
• Burrus B, Moscicki B, Matthews T, Paolone V. The effect of acute L-carnitine and carbohydrate intake on cycling performance. Int J Exerc Sci. 2018;11:404–16.
   Google Scholar
• Borghi-Silva A, Baldissera V, Sampaio LMM, Pires-DiLorenzo VA, Jamami M, Demonte A, et al. L-carnitine as an ergogenic aid for patients with chronic obstructive pulmonary disease submitted to whole-body and respiratory muscle training programs. Braz J Med Biol Res. 2006;39:465–74.
   PubMed Web of Science ®Google Scholar
• ALSUntangled Group. ALSUntangled 44: curcumin. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018;19:623–9.
   PubMed Web of Science ®Google Scholar
• Gulcin I. Antioxidant and antiradical activities of L-carnitine. Life Sci. 2006;78:803–11.
   PubMed Web of Science ®Google Scholar
• Vanella A, Russo A, Acquaviva R, Campisi A, Di Giacomo C, Sorrenti V, et al. L-propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biology and Toxicology. 2000;16:99–104.
   PubMed Web of Science ®Google Scholar
• Calabrese V, Ravagna A, Colombrita C, Scapagnini G, Guagliano E, Calvani M, et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res. 2005;79:509–21.
   PubMed Web of Science ®Google Scholar
• Abdul H, Calabrese V, Calvani M, Butterfield D. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1–42-mediated oxidative stress and neurotoxicity: implications for Alzheimer’s Disease. J Neurosci Res. 2006;84:398–408.
   PubMed Web of Science ®Google Scholar
• Hota K, Hota S, Chaurasia O, Singh S. Acetyl-L-carnitine-mediated neuroprotection during hypoxia is attributed to ERK1/2-Nrf2-regulated mitochondrial biosynthesis. Hippocampus. 2012;22:723–36.
   PubMed Web of Science ®Google Scholar
• Calabrese V, Colombrita C, Sultana R, Scapagnini G, Calvani M, et al. Redox modulation of heat shock protein expression by acetylcarnitine in aging brain: relationship to antioxidant status and mitochondrial function. Antioxid Redox Signaling. 2006;8:404–16.
   PubMed Web of Science ®Google Scholar
• Liu J, Head E, Kuratsune H, Cotman C, Ames B. Comparison of the effects of L-carnitine and acetyl-l-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann NY Acad Sci. 2004;1033:117–31.
   PubMed Web of Science ®Google Scholar
• Pignatelli P, Tellan G, Marandola M, Carnevale R, Loffredo L, et al. Effect of L-carnitine on oxidative stress and platelet activation after major surgery. Acta Anaesthesiologica Scandinavica. 2011;55:1022–8.
   PubMed Web of Science ®Google Scholar
• Cao Y, Qu HJ, Li P, Wang CB, Wang LX, Han ZW. Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. Tohoku J Exp Med. 2011;224:209–13.
   PubMed Web of Science ®Google Scholar
• Parandak K, Arazi H, Khoshkhahesh F, Nakhostin-Roohi B. The effect of two-week L-carnitine supplementation on exercise-induced oxidative stress and muscle damage. Asian J Sports Med. 2014;5:123–8.
   PubMedGoogle Scholar
• Lee BJ, Lin JS, Lin YC, Lin PT. Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: a randomized, placebo-controlled trial. Nutr J. 2014;13:79.
   PubMed Web of Science ®Google Scholar
• Mahdavi A, Mahdavi R, Kolahi S, Zemestani M, Vatankhah A. L-carnitine supplementation improved clinical status without changing oxidative stress and lipid profile in women with knee osteoarthritis. Nutr Res. 2015;35:707–15.
   PubMed Web of Science ®Google Scholar
• Armaly Z, El Qader AA, Jabbour A, Hassan K, Ramadan R, Bowirrat A, et al. Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype. BMC Nephrol. 2015;16:135.
   PubMed Web of Science ®Google Scholar
• Guzel N, Orer G, Bircan F, Cevher S. Effects of acute L-carnitine supplementation on nitric oxide production and oxidative stress after exhaustive exercise in young soccer players. The Journal of Sports Medicine and Physical Fitness. 2015;55:9–15.
   PubMed Web of Science ®Google Scholar
• Sachan D, Hongu N, Johnsen M. Decreasing oxidative stress with choline and carnitine in women. J Am Coll Nutr. 2005;24:172–6.
   PubMed Web of Science ®Google Scholar
• Bloomer R, Tschume L, Smith W. Glycine propionyl-L-carnitine modulates lipid peroxidation and nitric oxide in human subjects. International Journal for Vitamin and Nutrition Research. 2009;79:131–41.
   PubMed Web of Science ®Google Scholar
• Bloomer R, Smith W. Oxidative stress in response to aerobic and anaerobic power testing: influence of exercise training and carnitine supplementation. Research in Sports Medicine. 2009;17:1–16.
   PubMed Web of Science ®Google Scholar
• Loffredo L, Pignatelli P, Cangemi R, Andreozzi P, Panico MA, Meloni V, et al. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: Effect of an antioxidant treatment. Journal of Vascular Surgery. 2006;44:525–30.
   PubMed Web of Science ®Google Scholar
• Loffredo L, Carnevale R, Cangemi R, Angelico F, Augelletti T, Di Santo S, et al. NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. International Journal of Cardiology. 2013;165:184–92.
   PubMed Web of Science ®Google Scholar
• Bloomer R, Fisher-Wellman K, Tucker P. Effect of oral acetyl L-carnitine arginate on resting and postprandial blood biomarkers in pre-diabetics. Nutr Metab (Lond). 2009;6:25.
   PubMed Web of Science ®Google Scholar
• Balercia G, Regoli F, Armeni T, Koverech A, Mantero F, Boscaro M. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility. 2005;84:662–71.
   PubMed Web of Science ®Google Scholar
• Orrell R, Lane R, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2008;9:195–211.
   PubMed Web of Science ®Google Scholar
• Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505–12.
   PubMed Web of Science ®Google Scholar
• Smith E, Shaw P, De Vos K. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019;710:132933.
   PubMed Web of Science ®Google Scholar
• Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol. 2018;135:489–509.
   PubMed Web of Science ®Google Scholar
• Capecchi P, Laghi Pasini F, Quartarolo E, Di Perri T. Carnitines increase plasma levels of adenosine and ATP in humans. Vasc Med. 1997;2:77–81.
   PubMedGoogle Scholar
• King A, Woodhouse A, Kirkcaldie M, Vickers J. Excitotoxicity in ALS: overstimulation, or overreaction? Experimental Neurology. 2016;275:162–71.
   PubMed Web of Science ®Google Scholar
• Felipo V, Minana MD, Cabedo H, Grisolia S. L-carnitine increases the affinity of glutamate for quisqualate receptors and prevents glutamate neurotoxicity. Neurochem Res. 1994;19:373–7.
   PubMed Web of Science ®Google Scholar
• Bigini P, Larini S, Pasquali C, Muzio V, Mennini T. Acetyl-l-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. Neurosci Lett. 2002;329:334–8.
   PubMed Web of Science ®Google Scholar
• Babu G, Kumar A, Singh R. Chronic pretreatment with acetyl-L-carnitine and –DL-a-lipoic acid protects against acute glutamate-induced neurotoxicity in rat brain by altering mitochondrial function. Neurotox Res. 2011;19:319–29.
   PubMed Web of Science ®Google Scholar
• Mazzocchio R, Schieppati M, Scarpini C, Rossi A. Enhancement of recurrent inhibition by intravenous administration of L-acetylcarnitine in spastic patients. Journal of Neurology, Neurosurgery, and Psychiatry. 1990;53:321–6.
   PubMed Web of Science ®Google Scholar
• Miller R, Mitchell J, Moore D. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database for Syst Rev. 2012;3:CD001447.
   PubMed Web of Science ®Google Scholar
• Gouel F, Rolland A-S, Devedjian J-C, Burnouf T, Devos D. Past and future of neurotrophic growth factors therapies in ALS: from single neurotrophic growth factor to stem cells and human platelet lysates. Front Neurol. 2019;10:835
   PubMed Web of Science ®Google Scholar
• Forloni G, Angeretti N, Smiroldo S. Neuroprotective activity of ACETYL-L-carnitine: studies in vitro. J Neurosci Res. 1994;37:92–6.
   PubMed Web of Science ®Google Scholar
• Ishii T, Shimpo Y, Matsuoka Y, Kinoshita K. Anti-apoptotic effect of acetyl-l-carnitine and l-carnitine in primary cultured neurons. Jpnjpharmacol. 2000;83:119–24.
   Google Scholar
• De Angelis C, Scarfò C, Falcinelli M, Perna E, Reda E, Ramacci MT, et al. Acetyl-L-carnitine prevents age-dependent structural alterations in rat peripheral nerves and promotes regeneration following sciatic nerve injury in young and senescent rats. Experimental Neurology. 1994;128:103–14.
   PubMed Web of Science ®Google Scholar
• Hart A, Wilberg M, Terenghi G. Pharmacological enhancement of peripheral nerve regeneration in the rate by systemic acetyl-L-carnitine treatment. Neurosci Lett. 2002;334:181–5.
   PubMed Web of Science ®Google Scholar
• Wilson A, Hart A, Wiberg M, Terenghi G. Acetyl-L-carnitine increases nerve regeneration and target organ reinnervation. Journal of Plastic, Reconstructive and Aesthetic Surgery. 2010;63:1186–95.
   PubMed Web of Science ®Google Scholar
• Karalija A, Novikova L, Kingham P, Wiberg M, Novikov L. Neuroprotective effects of N-acetyl-cysteine and acetyl-L-carnitine after spinal cord injury in adult rats. PLoS One. 2012;7:e41086.
   PubMed Web of Science ®Google Scholar
• Kampinga H, Bergink S. Heat shock proteins as potential targets for protective strategies in neurodegeneration. Lancet Neurol. 2016;15:748–59.
   PubMed Web of Science ®Google Scholar
• Kalmar B, Lu CH, Greensmith L. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: the therapeutic potential of arimoclomol. Pharmacol Ther. 2014;141:40–54.
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Shefner J, Simpson E, Grasso D, Yu H. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve. 2008;38:837–44.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565–e574.
   PubMed Web of Science ®Google Scholar
• Personal communication (e-mail) between Jesse Crayle and Caterina Bendotti, PhD thesis. March 12, 2018.
   Google Scholar
• Beghi E, Pupillo E, Bonito V, Buzzi P, Caponnetto C, Chiò A, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2013;14:397–405.
   PubMed Web of Science ®Google Scholar
• Bigini P, Muzio V, De Angelis C, Mennini T. In vitro and in vivo effect of acetyl-L-carnitine on motor neuron degeneration. Neurosci Lett. 1999;S18:6.
   Google Scholar
• Kira Y, Nishikawa M, Ochi A, Sato E, Inoue M. L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res. 2006;1070:206–14.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler J-P, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotrophic Lateral Sclerosis. 2010;11:38–45.
   PubMed Web of Science ®Google Scholar
• Acetyl-L-Carnitine Treatment Report. PatientsLikeMe website. Available at: https://www.patientslikeme.com/treatment/acetyl-l-carnitine. Accessed January 5, 2020.
   Google Scholar
• L-Carnitine Treatment Report. PatientsLikeMe website. Available at: https://www.patientslikeme.com/treatment/l-carnitine. Accessed January 5, 2020.
   Google Scholar
• Harrison D, Mehta P, van Es M, Stommel E, Drory V, Nefussy B, et. al. ALS reversals: demographics, disease characteristics, treatments, and co-morbidities. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018;19:495–9.
   PubMed Web of Science ®Google Scholar
• Marin B, Bianchi E, Pupillo E, Lunetta C, Tremolizzo L, Logroscino G, et al. Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2016;17:77–84.
   PubMed Web of Science ®Google Scholar
• Montgomery S, Thal L, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. International Clinical Psychopharmacology. 2003;18:61–71.
   PubMed Web of Science ®Google Scholar
• Testa D, Caraceni T, Fetoni V, Girotti F. Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study. Clinical Neurology and Neurosurgery. 1992;94:7–9.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Invest. 2014;4:605–18.
   PubMedGoogle Scholar
• Hathcock J, Shao A. Risk assessment for carnitine. Regul Toxicol Pharm. 2006;46:23–8.
   PubMed Web of Science ®Google Scholar
• Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and safety of L-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials. BioMed Res Int. 2017;2017:1–11.
   Web of Science ®Google Scholar
• Meister R, von Wolff A, Mohr H, Härter M, Nestoriuc Y, Hölzel L, et al. Comparative safety of pharmacologic treatments for persistent depressive disorder: a systematic review and network meta-analysis. PLoS One. 2016;11:e0153380.
   PubMed Web of Science ®Google Scholar
• Brass E, Koster D, Hiatt W, Amato A. A systematic review and meta-analysis of propionyl-l-carnitine effects on exercise performance in patients with claudication. Vasc Med. 2013;18:3–12.
   PubMed Web of Science ®Google Scholar
• Uematsu T, Itaya T, Nishimoto M, Takiguchi Y, Mizuno A, Nakashima M, et al. Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. Eur J Clin Pharmacol. 1988;34:213–6.
   PubMed Web of Science ®Google Scholar
• Iver R, Gupta A, Khan A, Hiremath S, Lokhandwala Y. Does left ventricular function improve with L-carnitine after acute myocardial infarction? Journal of Postgraduate Medicine. 1999;45:38–41.
   PubMedGoogle Scholar
• Zhang J-j, Wu Z-b, Cai Y-j, Ke B, Huang Y-j, Qiu C-p, et al. L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study. Nutr J. 2014;13:110.
   PubMed Web of Science ®Google Scholar
• Puskarich M, Kline J, Krabill V, Claremont H, Jones A. Preliminary safety and efficacy of L-carnitine Infusion for the treatment of vasopressor-dependent septic shock. Jpen J Parenter Enteral Nutr. 2014;38:736–43.
   PubMed Web of Science ®Google Scholar
• Jing Z-C, Wu B-X, Peng J-Q, Li X-L, Pan L, Zhao S-P, et al. Effect of intravenous L-carnitine in Chinese patients with chronic heart failure. Eur Heart J Suppl. 2016;18:A27–A36.
   Web of Science ®Google Scholar
• Brevetti G, Perna S, Sabbà C, Rossini A, Scotto di uccio V, Berardi E, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. European Heart Journal. 1992;13:251–5.
   PubMed Web of Science ®Google Scholar
• Corsi C, Pollastri M, Marrapodi E, Leanza D, Giordano S, D’Iddio S. L-propionylcarnitine effect on postexercise and postischemic hyperemia in patients affected by peripheral vascular disease. Angiology 1995;46:705–13.
   PubMed Web of Science ®Google Scholar
• Ragozzino G, Mattera E, Madrid E, Salomone P, Fasano C, Gioia F, et al. Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease. Drugs R D. 2004;5:185–90.
   PubMedGoogle Scholar
• Montisci R, Ruscazio M, Lai S, Vacca A, Cauli A, Passiu G, et al. Effect of a single IV administration of L-propionylcarnitine on myocardial microcirculation assessed by coronary flow velocity reserve measurement in patients with systemic sclerosis: a pilot study. Clin Ther. 2007;29:163–71.
   PubMed Web of Science ®Google Scholar
• Allegra C, Antignani PL, Schachter I, Koverech A, Messano M, Virmani A. Propionyl-L-carnitine in leriche-fontaine stage II peripheral arterial obstructive disease. Ann Vasc Surg. 2008;22:552–8.
   PubMed Web of Science ®Google Scholar
• Di Biase M, Tritto M, Pitzalis M, Favale S, Rizzon P. Electrophysiologic evaluation of intravenous L-propionylcarnitine in man. Int J of Cardiology. 1991;30:329–33.
   PubMed Web of Science ®Google Scholar
• Li S, Li Q, Li Y, Li L, Tian H, Sun X. Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015;10:e0119479.
   PubMed Web of Science ®Google Scholar
• Ussher J, Lopaschuk G, Arduini A. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis. 2013;231:456–61.
   PubMed Web of Science ®Google Scholar
• Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576–85.
   PubMed Web of Science ®Google Scholar
• Zeisel S, Warrier M. Trimethylamine N-oxide, the microbiome, and heart and kidney disease. Annu Rev Nutr. 2017;37:157–81.
   PubMed Web of Science ®Google Scholar
• Heianaza Y, Ma W, Manson J, Rexrode K, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J Am Heart Assoc 2017;6:e004947.
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O’Keefe JH. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clinic Proceedings. 2013;88:544–51.
   PubMed Web of Science ®Google Scholar
• Dambrova M, Liepinsh E. Risks and benefits of carnitine supplementation in diabetes. Exp Clin Endocrinol Diabetes. 2015;123:95–100.
   PubMed Web of Science ®Google Scholar
• Xu Y, Jiang W, Chen G, Zhu W, Ding W, Ge Z, et al. L-carnitine treatment of insulin resistance: a systematic review and meta-analysis. Adv Clin Exp Med. 2017;26:333–8.
   PubMed Web of Science ®Google Scholar
• Bain M, Milne R, Evans A. Disposition and metabolite kinetics of oral L-carnitine in humans. Journal of Clinical Pharmacology. 2006;46:1163–70.
   PubMed Web of Science ®Google Scholar
• Harper P, Elwin C, Cederblad G. Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. Eur J Clin Pharmacol. 1988;35:555–62.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang Y, Liu C, Wang L, Han Z, Wang C. Comparison of pharmacokinetics of L-carnitine, Acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. Cim. 2009;32:13– E19.
   Google Scholar
• Pace S, Longo A, Toon S, Rolan P, Evans A. Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. J Clin Pharmacol. 2001;50:441–8.
   Web of Science ®Google Scholar
• Sano M, Bell K, Cote L, Dooneief G, Lawton A, Legler L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer’s Disease. Arch Neurol. 1992;49:1137–41.
   PubMed Web of Science ®Google Scholar
• Parnetti L, Gaiti A, Mecocci P, Cadini D, Senin U. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol. 1992;42:89–93.
   PubMed Web of Science ®Google Scholar
• Acetyl-L-Carnitine Search Results. Amazon.com website. Available at: https://www.amazon.com/s?k=acetyl-+l-+carnitine. Accessed January 6, 2020.
   Google Scholar